Lumos Diagnostics Holdings Limited announced that its Board of Directors has appointed Doug Ward, a highly experienced diagnostics executive, to serve as CEO. Mr. Ward has held executive positions including CEO during his more than 30-year career. Most recently he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in womens healthcare to improve clinical results.

Prior to joining Hologic, Mr. Ward was the CEO of Personal Genome Diagnostics (PGDx) where he led the organizations transformation from a clinical laboratory testing service into a fully functional molecular in vitro diagnostics company. Mr. Ward joins Lumos Diagnostics at a pivotal time in the Companys history. Lumos is actively preparing for the commercial launch of its novel point-of-care test, FebriDx, in the U.S. pending the receipt of a 510(k) clearance from the FDA.

In addition, applications for regulatory clearance of Lumos ViraDx and CoviDx point-of-care tests have been filed in key markets such as Canada and Australia.